Search Within

Andrew D Zelenetz

Formats
  1. Meeting Abstract (461)
  2. Journal Article (288)
  3. Research Letter (14)
  4. Book Section (7)
  5. Guidelines (5)
  6. Conference Paper (3)
  7. Correspondence (3)
  8. Editorial (3)
  9. Review (1)
Groups
  1. Center for Hematologic Malignancies (785)
  2. Department of Medicine (785)
  3. Hematologic Malignancies, Division of (785)
  4. Lymphoma (785)
  5. Survivorship Research (234)
  6. Population Sciences Research Program (189)

More Groups

People
  1. Craig Moskowitz (207)
  2. Ariela Noy (188)
  3. Paul Hamlin (187)
  4. Steven Horwitz (169)
  5. David Straus (163)
  6. Maria Palomba (143)

More People

Years
  1. 2025 (8)
  2. 2024 (31)
  3. 2023 (43)
  4. 2022 (30)
  5. 2021 (29)
  6. 2020 (32)

More Years

Publications
  1. Blood (329)
  2. Journal of Clinical Oncology (83)
  3. Journal of the National Comprehensive Cancer Network (35)
  4. British Journal of Haematology (34)
  5. Leukemia and Lymphoma (31)
  6. Annals of Oncology (26)

More Publications

Publishers
  1. American Society of Hematology (341)
  2. American Society of Clinical Oncology (85)
  3. John Wiley & Sons (41)
  4. Harborside Press (35)
  5. Elsevier Inc. (31)
  6. Oxford University Press (31)

More Publishers

Results (785)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era
    Research Letter

    Qualls, D.; Imber, B. S.; Okwali, M.; Hamlin, P. A.; Kumar, A.; Lahoud, O. B.; Matasar, M. J.; Noy, A.; Owens, C.; Zelenetz, A. D.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Interim positron emission tomography during frontline chemoimmunotherapy for follicular lymphoma
    Journal Article

    Merryman, R. W.; Michaud, L.; Redd, R.; Mondello, P.; Park, H.; Spilberg, G.; Robertson, M.; Taranto, E.; Ahmed, G.; Chase, M.; more...
    HemaSphere (2023)

    Fulltext@MSK | Save
  • Primary efficacy and safety analysis of a global phase II study of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): The TIDAL study
    Meeting Abstract

    Phillips, T.; Jurczak, W.; Ribrag, V.; Linton, K.; Collin, G. P.; Lopéz-Jimenéz, J.; Reddy, N.; Mengarelli, A.; Musuraca, G.; Sheehy, O.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Outcomes of therapies and resistance mutations following non-covalent Bruton's Tyrosine Kinase inhibitor treatment for patients with chronic lymphocytic leukemia and Richter Transformation
    Meeting Abstract

    Thompson, M. C.; Coombs, C. C.; Roeker, L. E.; Jensen, J. L.; Shah, N. N.; Luo, T.; Patel, K.; Bailey, N.; Fakhri, B.; Eyre, T. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Characterization of a large cohort of patients with nodal marginal zone lymphoma shows prolonged survival, time-to-treatment, and time-to-transformation
    Meeting Abstract

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed / refractory mantle cell lymphoma: Additional patients and extended follow-up from the phase 1/2 BRUIN study
    Meeting Abstract

    Wang, M. L.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C. Y.; Ujjani, C. S.; Koh, Y.; Izutsu, K.; Gerson, J. N.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • LymphGen classification of diffuse large B-cell lymphoma in a cohort of adolescent and young adult (AYA) patients
    Meeting Abstract

    Cabal, A.; Zhu, M.; Uppal, M.; Joffe, E.; Batlevi, C. L.; Matasar, M. J.; Okwali, M.; Dogan, A.; Zelenetz, A. D.; Salles, G.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Long-term outcome of patients with follicular lymphoma is not fundamentally affected by KMT2D, EZH2, and CREBBP mutational status
    Meeting Abstract

    Bantilan, K. S.; Rutherford, K.; McCarter, J.; Farnoud, N.; Arango-Ossa, J. E.; Papaemmanuil, E.; Zelenetz, A. D.
    Blood (2022)

    Fulltext@MSK | Save